Pre-meal inhaled insulin lowers HbA1c levels more effective than rosiglitazone
Inhaled insulin (Exubera, Pfizer/Sanofi-Aventis) could be an effective therapy and alternative to rosiglitazone (Avandia, GlaxoSmithKline) for individuals who are early into the course of type 2 diabetes, according to a study published in Diabetes Care.
Inhaled insulin (Exubera, Pfizer/Sanofi-Aventis) could be an effective therapy and alternative to rosiglitazone (Avandia, GlaxoSmithKline) for individuals who are early into the course of type 2 diabetes, according to a study published in Diabetes Care.
The multicenter trial involved 145 individuals whose type 2 diabetes was not controlled adequately by diet and exercise alone (HbA1c, 8%–11%). The patients' mean age was 54 and their mean baseline HbA1c level was 9.5%.
Each subject was randomized to 3 months of treatment with either inhaled insulin (INH) before meals (n=76) or rosiglitazone 4 mg twice a day (n=69), in conjunction with a diet and exercise program. Seventy-one and 63 patients from each treatment group, respectively, completed the study. The primary end point was the percentage of patients achieving HbA1c <8.0% at 12 weeks or at the time of discontinuation.
The favorable inhaled insulin results were also similar at the American Diabetes Association-recommended HbA1c value of <7.0% (44% vs 17.9%; adjusted OR, 4.43; 95% CI, 1.94–10.12) and the American Association of Clinical Endocrinologists-recommended HbA1c value of #6.5% (28% vs 7.5%; adjusted OR, 5.34; 95% CI, 1.83–15.57).
The absolute reduction in HbA1c at Week 12 was greater in the INH group (–2.3% vs –1.4%; adjusted treatment group difference, –0.89%; 95% CI, –1.23 to –0.55), with mean final HbA1c values of 7.2% and 8.0% for INH and rosiglitazone, respectively.
"To our knowledge, this represents the only demonstration that American Diabetes Association goals for glycemic control can be achieved in many type 2 diabetes patients using only a rapid-acting insulin," the authors stated.
Noting that rosiglitazone may take 18 or more weeks to achieve peak glucose-lowering activity, the authors stated that it "cannot be ruled out that a longer study duration may have resulted in greater glucose lowering in the rosiglitazone arm."
Hypoglycemic episodes occurred significantly more often in the inhaled-insulin group than in the rosiglitazone group (0.7 vs 0.05 episodes per patient-month, respectively; risk ratio, 14.72; 95% CI, 7.51–28.83). However, no severe hypoglycemic episodes were reported by any patients in the INH group.
SOURCE DeFronzo RA, Bergenstal RM, Cefalu WT, et al. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise. Diabetes Care. 2005;28:1922–1928.
Medicare’s Drug Price Negotiations Could Impact Physician Reimbursement
September 19th 2024When CMS begins negotiations for physician-administered drugs under the Inflation Reduction Act, providers, including those whose services are covered by commercial insurance, could see lowered reimbursement.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
Diabetes Management & Telehealth with Leslie Kolb
June 11th 2020Association of Diabetes Care and Education Specialists, chief science and practice officer, Leslie Kolb chats with MHE Associate Editor Briana Contreras in MHE's newest podcast Tuning into the C-Suite about diabetes management and how it's affected by the use of telehealth, especially during the current and trying times of the COVID-19 pandemic.
Listen
